培美曲塞联合顺铂治疗晚期肺腺癌的疗效观察  

Effect of the pemetrexed combined with cisplatin in the treatment of advanced lung adenocarcinoma

作　　者：武文娟[1] 陈丽[1] 蒋亚齐[1] 王朝敏[1] 

机构地区：[1]江苏省苏北人民医院肿瘤科,江苏扬州225001

出　　处：《蚌埠医学院学报》2015年第11期1529-1531,共3页Journal of Bengbu Medical College

摘　　要：目的:观察培美曲塞联合顺铂治疗晚期肺腺癌的疗效及不良反应。方法:选择136例Ⅲ/Ⅳ期肺腺癌患者,随机分为观察组和对照组,各68例。其中,对照组采用紫杉醇联合顺铂治疗,观察组采用培美曲塞联合顺铂治疗,观察2组患者的疗效及不良反应。结果:观察组总有效率及疾病控制率分别为50.0%、97.1%,均优于对照组的30.9%、82.4%(P<0.01);观察组患者的生存率为98.5%,高于对照组的83.8%(P<0.01)。观察组白细胞及血小板减少的发生率均低于对照组(P<0.05)。结论:培美曲塞联合顺铂治疗晚期肺腺癌患者疗效较好,且不良反应小,患者耐受性较好。Objective： To observe the effects and adverse reactions of pemetrexed combined with cisplatin in the treatment of advanced lung adenocarcinoma. Methods： One hundred and thirty-six patients with stage Ⅲ / Ⅳ lung adenocarcinoma were randomly divided into the control group and experimental group（ 68 cases each group）. The control group and experimental group were treated with pemetrexed combined with cisplatin and paclitaxel combined with cisplatin,respectively. The efficacy and adverse reactions in two groups were evaluated. Results： The total effective rate and disease control rate in the experimental group were 50. 0% and 97. 1%,respectively,which was significantly better than the total efficiency（ 30. 9%） and disease control rate（ 82. 4%） in the control group（ P〈0. 01）. The survival rate in experimental group（ 98. 5%） was significantly higher than that in the control group（ 83. 8%）（ P〈0. 01）. The incidence rates of leukopenia and thrombocytopenia in the experimental group were significantly lower than those in the control group（ P〈0. 05）. Conclusions： The treatment of advanced lung cancer with pemetrexed combined with cisplatin is good effects,little side effects and good tolerance.

关 键 词：肺肿瘤 培美曲塞 顺铂 紫杉醇 

分 类 号：R734.2[医药卫生—肿瘤]